São Paulo - Delayed Quote BRL
Novo Nordisk A/S (N1VO34.SA)
44.21
+0.70
+(1.61%)
At close: April 24 at 5:05:00 PM GMT-3
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Cash Flow
120,968,000
120,968,000
108,908,000
78,887,000
55,000,000
Investing Cash Flow
-128,895,000
-128,895,000
-43,892,000
-24,918,000
-31,605,000
Financing Cash Flow
8,735,000
8,735,000
-63,158,000
-51,797,000
-25,493,000
End Cash Position
15,655,000
15,655,000
14,392,000
12,653,000
10,719,000
Capital Expenditure
-51,309,000
-51,309,000
-38,896,000
-14,753,000
-7,385,000
Issuance of Debt
79,391,000
79,391,000
--
11,215,000
22,160,000
Repayment of Debt
-6,335,000
-6,335,000
-1,467,000
-13,623,000
-6,689,000
Repurchase of Capital Stock
-20,181,000
-20,181,000
-29,924,000
-24,086,000
-19,447,000
Free Cash Flow
69,659,000
69,659,000
70,012,000
64,134,000
47,615,000
12/31/2021 - 10/20/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade